CPC A61K 31/352 (2013.01) [A61K 9/0019 (2013.01); A61K 31/21 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2875 (2013.01)] | 15 Claims |
1. A method of treating a mammalian subject having multiple myeloma comprising the steps of:
(A) administering a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium to a mammalian subject having multiple myeloma; and
(B) maintaining said mammalian subject for a period of time sufficient to induce death of said multiple myeloma cells,
wherein said first cancer cytotoxic agent halogenated xanthene, pharmaceutically acceptable salt or C1-C4 alkyl ester thereof is rose bengal disodium salt.
|